共 992 条
[91]
Bessler N(2020)Current and future treatments in Alzheimer disease: an update J Cent Nerv Syst Dis 29 133-325.e13
[92]
Figler K(2018)Levodopa-induced dyskinesia: clinical features, incidence, and risk factors J Neural Transm 125 1-596
[93]
Buchholz MB(2018)Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study Neurology 91 574-683
[94]
Rios AC(2019)Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations CNS Drugs 33 1-694
[95]
Malda J(2020)Trehalose against Alzheimer’s disease: insights into a potential therapy BioEssays 42 15-33618
[96]
Fouke KE(2019)Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer’s disease Ann Clin Transl Neurol 6 3501-10798
[97]
Wegman ME(2021)Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys Brain 144 2216-1958
[98]
Weber SA(2022)Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: a case report Front Oncol 18 40-1871
[99]
Brady EB(2021)Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer’s disease Alzheimer’s & Dementia 7 117-1281
[100]
Román-Vendrell C(2021)A phase 1 study of AL002 in healthy volunteers Alzheimer’s & Dementia 17 1064-187